Onco-Innovations Reports Progress Toward a Consistent and Scalable Polymer Manufacturing Process Supporting ONC010

Calgary, Canada – July 30, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) (“Onco“ or the “Company”) is pleased to announce, further to its news release dated June 30, 2026, progress with respect to its collaborative polymer development program with Nanosoft Polymers (“Nanosoft“), including process optimization and catalyst evaluation activities aimed at improving the consistency and uniformity of the polymer used in ONC010’s nanoparticle formulation. The work forms part of the chemistry, manufacturing and controls (“CMC“) development of ONC010, the Company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (“PNKP“) inhibitor.

A central focus of the current work is the evaluation of catalyst systems and refinement of polymer synthesis conditions and reaction parameters aimed at improving control of the polymer’s polydispersity index (“PDI“), a key measure of molecular weight uniformity. Greater control of PDI is expected to support more consistent polymer characteristics, nanoparticle formation, formulation performance and batch-to-batch manufacturing reproducibility. The ongoing program is focused on developing a robust manufacturing process for Onco’s proprietary PEO-PBCL block copolymer, a key component of the nanoparticle delivery platform used in ONC010. Onco and Nanosoft are also advancing analytical characterization and scale-up activities intended to help define critical manufacturing parameters and support future good manufacturing practice (“GMP“) production and clinical development.

Since initiating the program, Nanosoft has advanced multiple technical workstreams establishing critical manufacturing parameters. Emphasis has been placed on catalyst selection and reaction optimization to improve polymer consistency while refining purification strategies and manufacturing efficiency.

“Establishing a scalable and reproducible polymer manufacturing process is fundamental to the successful further development of nanoparticle therapeutics. We are pleased with the progress Nanosoft has made in advancing the optimization of our polymer platform and believe these activities further strengthen the manufacturing foundation supporting ONC010’s future development. By investing early in process optimization and analytical development, we are working to reduce manufacturing risk while positioning the program for future clinical and commercial scalability,“ stated Thomas O’Shaughnessy.

Chief Executive Officer of Onco-Innovations.

The Company expects polymer process optimization, analytical characterization and scale-up activities to continue over the coming months as part of its broader CMC strategy supporting ONC010. These efforts are intended to facilitate future technology transfer, GMP manufacturing and regulatory submissions while enhancing long-term manufacturing robustness.

“Nanoparticle therapeutics require the same level of precision in polymer engineering as they do in pharmaceutical development. Building a well-characterized, reproducible polymer platform today can materially strengthen the quality of the final drug product and support a smoother path through regulatory review and clinical development,“ stated Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy”

Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

Forward-Looking Statements Caution.   This news release contains forward-looking statements, including in relation to the Company’s research and development plans, business and plans generally, and other statements that are not historical facts, including in relation to the anticipated benefits of the relationship with Nanosoft, and its future research and development plans. Forward-looking statements are often identified by terms such as “will”, “may”, “potential”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Important factors that could cause actual results to differ materially from expectations include, without limitation, the Company’s ability to successfully integrate Nanosoft’s services into the Company’s development program, the results of research and development activities, the availability of financing, the ability to maintain contractual and commercial relationships, the ability to obtain and maintain regulatory approvals, risks relating to clinical development and commercialization, and general economic, market and industry conditions. 

 
Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, including those discussed in the Company’s public disclosure record. In particular, the Company may not be able to derive any benefit from its relationship with Nanosoft, and may not be able to carry out its research and development plans for a variety of reasons, including, but not limited to, the failure to receive regulatory approvals, the failure to maintain contractual relations, delays in development timelines, adverse results from research activities, or the failure to obtain financing and retain key personnel. 

 
The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company undertakes no obligation to update or revise publicly any forward-looking statements except as expressly required by applicable law.